EN
抗体药类似物
Research Grade Rimteravimab
All
TD-VK565166_1.jpg
  • CatalogTD-VK565166
  • ClonalitymAb
  • Application Research Grade Biosimilar
  • SynonymsVHH-72-Fc,XVR011CAS:2540797-21-3
  • 规格
    1mg
  • 价格
    ¥询价
定制服务咨询

Research Grade Rimteravimab


Catalog No. TD-VK565166
Species reactivity SARS-CoV-2 (2019-nCoV)
Applications Research Grade Biosimilar
Host species Chimeric
Isotype [VH-h-CH2-CH3]-dimer
Expression system Mammalian Cells
Clonality Monoclonal
Target Spike glycoprotein, S glycoprotein, E2, Peplomer protein, Spike protein S1, Spike protein S2, Spike protein S2', S, 2, Receptor-Binding Domain, RBD
Endotoxin level Please contact the lab for this information.
Purity >95% purity as determined by SDS-PAGE.
Purification Protein A/G, purified from cell culture supernatant.
Accession P0DTC2-2
Form Liquid
Storage buffer 0.01M PBS,pH7.4.
Stability and Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Alternate Names VHH-72-Fc,XVR011CAS:2540797-21-3
Background Rimteravimab (XVR011) is a bivalent VHH-Fc antibody with potent neutralizing activity with high stability, broad coverage and silenced Fc effector functions against the disease caused by SARS-CoV-2.
Note For research use only. Not for use in clinical or therapeutic applications.

 

TD-VK565166_1.jpg
Bioactivity
 
Detects Recombinant SARS-CoV-2 Spike protein receptor binding domain (Cat No.: TD-VK565021) in indirect ELISA.